Document Type
Article
Original Publication Date
1990
Journal/Book/Conference Title
Antimicrobial Agents and Chemotherapy
Volume
34
Issue
6
First Page
1146
Last Page
1149
DOI of Original Publication
10.1128/AAC.34.6.1146
Date of Submission
November 2015
Abstract
Biliary pseudolithiasis has been reported in patients who received ceftriaxone therapy. To examine this phenomenon further, serial gallbladder sonograms were evaluated in 44 adult patients who received intravenous ceftriaxone at 2 g or a placebo daily for 14 days in a double-blind controlled study. Ultrasound examinations of gallbladders were performed on days 1 and 14 of therapy and 2 weeks posttherapy if abnormalities were observed on day 14. Eight patients were unevaluable because of abnormal base-line gallbladder sonograms. Thirty-six patients (ceftriaxone, n = 28; placebo, n = 8) demonstrated normal baseline gallbladder sonograms and were evaluated for the development of change. A total of 6 of 28 (21.4%) ceftriaxone-treated patients and 1 of 8 (12.5%) patients who received the placebo demonstrated abnormal gallbladder sonograms on day 14 (P = 0.491). Four of the six ceftriaxone-treated patients demonstrating abnormal sonograms were clinically asymptomatic, while two patients reported vomiting. The abnormal sonograms of gallbladders of patients treated with ceftriaxone returned to normal between 9 and 26 days posttherapy. These data suggest an association between ceftriaxone treatment and the development of gallbladder abnormalities on ultrasound examination which resolve spontaneously on discontinuation of ceftriaxone therapy.
Rights
Copyright © 1990, American Society for Microbiology
Is Part Of
VCU Pharmacotherapy and Outcomes Science Publications
Comments
Originally published at http://dx.doi.org/10.1128/AAC.34.6.1146. At time of publication, Gary R. Matzke was at University of Minnesota.